Navigation Links
EpCAM in Medical News

Micromet, Inc. Reports Second Quarter 2009 Financial Results

...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do...clonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with ...

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet, Inc. Reports First Quarter 2009 Financial Results

... The data indicate that only cancer cells have an active signaling form of epcam that promotes tumor formation. This data further supports the scientific a...umors. Its human monoclonal antibody adecatumumab, or MT201, also binds to epcam and is being developed under a collaboration with Merck Serono. The current...

Micromet, Inc. Reports Second Quarter 2008 Financial Results

...antibody targeting MCSP with potential use in the treatment of melanoma. -- Animal data suggested a therapeutic window for a BiTE antibody targeting epcam in a relevant animal species. Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "We have made s...

Micromet, Inc. Reports First Quarter 2008 Financial Results

...eting MCSP with potential use in the treatment of melanoma. -- Animal data suggest a therapeutic window of a BiTE antibody targeting epcam in a relevant animal species. -- In March, Micromet established a scientific advisory board and named five leading oncology and immunology resear...

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

...ddition to current studies of MT103, three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. BiTE is a registe...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora...

Micromet's BiTE(R) Antibodies Reveal Unique Mode of Action

...ced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About Micromet, In...age antibody is adecatumumab (MT201), a human monoclonal antibody targeting epcam expressing tumors. Adecatumumab is being developed by Micromet in collabora...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

...has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting epcam (CD326), CEA and MCSP, are in pre-clinical development. About MT103 (MEDI-538) MT103, which is being co-developed with MedImmune as MEDI-538, is a B...
EpCAM in Medical Technology

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

...ch (AACR) demonstrated MT110 can direct T cells to eliminate EpCAM-expressing human colorectal cancer stem cells in cell culture and in animal models. epcam is a target antigen that is highly and frequently expressed on many types of solid tumors. MT110 currently is in a phase 1 dose-escalating clinical t...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

...ignificant room for improvement in these patients. epcam is a cancer target which is highly expressed in co...pressed target antigen on colorectal cancer cells, epcam has recently been shown to drive tumor growth and ...ancer. In this trial, patients with high levels of epcam expression, in a dose-dependent fashion, developed...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

...is found in approximately 35 to 40 percent of patients with this disease. "Given that more than 95 percent of colon cancer patients strongly express epcam on their tumors, and that 35 to 40 percent of patients who have a KRAS mutant tumor may not benefit from treatment with anti-EGFR antibodies, adecatum...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

...ome for breast cancer patients with high epcam expression BETHESDA, Md., Sept. 15 /PRNewswire-F...igh EpCAM expression compared to patients with low epcam expression(2). The ongoing phase 1b clinical tri...as no responses were detected in patients with low epcam expression (0 of 8 patients). "These data demons...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

...19, and has provided proof-of-concept in an ongoing phase 1 clinical trial in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

...19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting epcam (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with l...
EpCAM in Biological Technology

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

Findings Support Development of Micromet's EpCAM-specific Antibody Therapeutics BETHESDA, Md., Jan. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune d...

Micromet Closes $80.5 Million Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Announces Pricing of Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Announces Public Offering of Common Stock

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Added to Russell 3000 Index

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

...cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to epcam and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after com...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... in breast cancer patients with high expression of epcam ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ ...n 1.0] was 38% in patients with high expression of epcam (n=8), the target of adecatumumab, compared to 9% in patients with low epcam expression (n=11). Patients treated with higher do...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

...he epithelial cell adhesion molecule, or EpCAM, a target antigen that is highly and frequently expressed on the surface of many types of solid tumors. epcam also has been shown to be expressed on cancer stem cells (2) and to promote tumor formation (3). The data presented at AACR show that the BiTE antibod...
EpCAM in Biological Products

CELLection Epithelial Enrich from Dynal Biotech

Description:... The kit contains 5 ml CELLection Dynabeads (4.5 m) coated with the monoclonal antibody against the human epithelial antigen epcam and DNase Releasing Buffer. For up to 5 log enrichment of epithelial tumour cells directly from blood, bone marrow or MNC. Tumour cells clumps can be...
Company:Dynal Biotech

Dynabeads Epithelial Enrich from Dynal Biotech

Description:... The product contains 5 ml Dynabeads® (4.5 μm) coated with the monoclonal BerEP4 against the human epithelial antigen, epcam (epithelial cell adhesion molecule). Also available in 40 samples of 2 x 10e7 MNC in 1 ml volume (contains 1 ml Dynabeads®, Cat.No 161.01)...
Company:Dynal Biotech
Other Tags
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX presents ... brand Juvéderm. Voluma XC treats volume loss in cheeks, ... Hendrick is pleased to be able to offer this ... clients. , Voluma is the first and only injectable ... mid-face and cheek area. This non-invasive treatment targets volume ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- All children ... 3 and 6, preferably every year, eye experts say. ... from an expert panel of the U.S. National Center ... children in this age group require screening for eye ... glasses, such as amblyopia ("lazy eye") and strabismus (a ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The cost of ... well-being, a new study finds. Researchers examined data ... been diagnosed with colorectal or lung cancer. Of those ... cancer-free, and more than 100 had advanced cancer. ... to pay their medical bills, which was linked with ...
(Date:12/19/2014)... Dennis Thompson HealthDay Reporter ... Ebola,s entrance into the United States -- along with ... outbreak -- have highlighted cracks in the nation,s public ... health policy report released Thursday. Half of U.S. ... to infectious disease outbreaks. That was the main conclusion ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
Other Contents